Epigenetic reprogramming of cancer stem cells to tumor cells using ultrasmall gold nanoparticle

Abstract

Epigenetic reprogramming of cancer stem-like cells (CSC) is crucial to the clinical implementation of efficient tumor management. Groups of methylation on genomic DNA are a relatively stable epigenetic component. They are key drivers in the formation and maintenance of CSCs. Hence, reprogramming the DNA methylation epigenetics can provide new insights into cancer therapeutic approaches. Nanoprobes can influence CSC epigenetics; however, existing nanoprobes induce epigenetic alterations in an unregulated manner, which might result in undesirable mutation accumulation, which can hinder the reprogramming process. Here we report an epigenetic reprogramming approach with an ultrasmall Au NP, which can demethylate the genomic DNA, thereby causing the reprogramming of CSCs to cancer cells. In vitro bench top verification on preclinical models of non-metastatic and metastatic lung CSC showed a significant decrease in genetic, phenotypic stemness, and cell cycle quiescence, validated with biological assays. Furthermore, the ultrasmall Au NP was shown to interact with the epigenetic environment of CSCs through gold-DNA affinity spectral analysis. The pilot clinical validation study established the potential of our approach for clinical implementation. To the best of our knowledge, this is the first study to demonstrate a CSC epigenetic reprogramming using nanoparticles. In summary, this paper demonstrated that the nanoprobe could actively modify epigenetics and, as a result, can be employed to mitigate CSC stemness. Our findings might pave the path for more effective anti-cancer treatments and precision nanomedicine in the future.